Choice
About

A clear goal: every child desired.

Choice started with a simple conviction: every child should be desired. For that, contraception has to be something you can switch on and off, without hormones and without having to think about it every day. Peter van de Graaf, an industrial designer with thirty years in medical product development, set out to build exactly that, in Eindhoven, on the former Philips site.

Portrait of Peter van de Graaf, founder and CEO of Choice
Peter van de Graaf, founder and CEO.
01Advisors

Gynaecologists and engineers.

An advisory board with experience in tubal implants, women's health innovation, reproductive biology and medical device regulation.

Prof. Bas VeersemaGynaecologist, specialist in tubal implants · UMC Utrecht
Dr. Peggy GeominiGynaecologist · Máxima MC · associate professor, Maastricht University
Dr. Abraham (Nick) MorseObstetrician-gynaecologist, women's health innovation · Boston
Dr. Cindy BasinskiObstetrician-gynaecologist · Indiana
Prof. Peter BaltusEngineer, wireless technology · TU Eindhoven
Dr. Peter VosVeterinary specialist, reproductive system · Utrecht University
Dr. Joris BannenbergMedical device regulation and clinical studies
02Network

Who we work with.

A small company with specialists in every part of the chain, from fine mechanics to reimbursement.

Máxima MC/UMC Utrecht/TU Eindhoven/Hubrecht Institute/MERLN, Maastricht University/Utrecht University/DQS/Bevinced/Stindt Consultancy/FemTech.nl/Brabant Startup Fonds/MeKo/Adcim/TN Tech/EP Flex/Zeus/SilMach

03Intellectual property

Protected where it matters.

Three patent families cover the system as a whole, the valve and its mode switch, with patents granted in Europe and the United States. How the valve, stent and endoscope are made is kept as know-how.

Rendering of the Choice valve in its stent, open
04Press

Press enquiries.

For interviews, images and background information, please contact Peter van de Graaf.

peter@choice.nu

In the press
May 2026
Het Financieele Dagblad · Klepjes in eileiders als ultiem anticonceptiemiddel

We are preparing the next round.

To take Choice through its first studies in women. Investor materials are shared under confidentiality.